全文获取类型
收费全文 | 2180篇 |
免费 | 390篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 97篇 |
儿科学 | 64篇 |
妇产科学 | 34篇 |
基础医学 | 177篇 |
口腔科学 | 15篇 |
临床医学 | 465篇 |
内科学 | 427篇 |
皮肤病学 | 10篇 |
神经病学 | 401篇 |
特种医学 | 89篇 |
外科学 | 406篇 |
综合类 | 11篇 |
预防医学 | 117篇 |
眼科学 | 112篇 |
药学 | 49篇 |
肿瘤学 | 114篇 |
出版年
2023年 | 51篇 |
2022年 | 18篇 |
2021年 | 41篇 |
2020年 | 58篇 |
2019年 | 47篇 |
2018年 | 77篇 |
2017年 | 106篇 |
2016年 | 96篇 |
2015年 | 105篇 |
2014年 | 116篇 |
2013年 | 156篇 |
2012年 | 87篇 |
2011年 | 76篇 |
2010年 | 102篇 |
2009年 | 136篇 |
2008年 | 75篇 |
2007年 | 77篇 |
2006年 | 81篇 |
2005年 | 80篇 |
2004年 | 79篇 |
2003年 | 76篇 |
2002年 | 61篇 |
2001年 | 62篇 |
2000年 | 54篇 |
1999年 | 46篇 |
1998年 | 39篇 |
1997年 | 34篇 |
1996年 | 36篇 |
1995年 | 29篇 |
1994年 | 19篇 |
1993年 | 15篇 |
1992年 | 40篇 |
1991年 | 36篇 |
1990年 | 22篇 |
1989年 | 26篇 |
1988年 | 28篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 23篇 |
1984年 | 24篇 |
1983年 | 13篇 |
1982年 | 14篇 |
1979年 | 21篇 |
1978年 | 10篇 |
1976年 | 12篇 |
1972年 | 10篇 |
1971年 | 10篇 |
1970年 | 17篇 |
1968年 | 10篇 |
1965年 | 9篇 |
排序方式: 共有2588条查询结果,搜索用时 15 毫秒
101.
Sydney Pettygrove PhD Zhenqiang Lu PhD Jennifer G. Andrews MBA F. John Meaney PhD Daniel W. Sheehan MD Elinora T. Price BA Deborah J. Fox MPH Shree Pandya PT DPT Lijing Ouyang PhD Susan D. Apkon MD Zoe Powis MS Christopher Cunniff MD 《Muscle & nerve》2014,49(6):814-821
Introduction: The correlation of markers of disease severity among brothers with Duchenne or Becker muscular dystrophy has implications for clinical guidance and clinical trials. Methods: Sibling pairs with Duchenne or Becker muscular dystrophy (n = 60) were compared for ages when they reached clinical milestones of disease progression, including ceased ambulation, scoliosis of ≥ 20°, and development of cardiomyopathy. Results: The median age at which younger brothers reached each milestone, compared with their older brothers ranged from 25 months younger for development of cardiomyopathy to 2 months older for ceased ambulation. For each additional month of ambulation by the older brother, the hazard of ceased ambulation by the younger brother decreased by 4%. Conclusions: The ages when siblings reach clinical milestones of disease vary widely between siblings. However, the time to ceased ambulation for older brothers predicts the time to ceased ambulation for their younger brothers. Muscle Nerve 49 : 814–821, 2014 相似文献
102.
103.
Rui Vieira MD Elena Segura-Grau MD Juliana Magalhães MD Joseph dos Santos PT MSc Luís Patrão MD 《Journal of clinical ultrasound : JCU》2020,48(7):431-434
Lung ultrasound (LUS) is becoming an invaluable tool in the management of critically ill patients. We report two cases showing the importance of LUS as a guide to optimize respiratory physiotherapy in the intensive care unit, allowing a successful lung donation process and to redirect the physiotherapist's approach. The use of LUS requires an adequate training but it is becoming an important tool in management algorithms for critically ill patients. 相似文献
104.
Shao-Yu Tsai PhD RN Wang-Tso Lee PhD MD Chien-Chang Lee PhD MD Suh-Fang Jeng ScD PT Wen-Chin Weng PhD MD 《Research in nursing & health》2020,43(2):168-175
We conducted a cross-sectional study to examine sleep in mothers of children with epilepsy and its relation to their children's sleep. A total of 133 dyads of mothers and children with epilepsy aged 1.5–6 years were recruited between 2015 and 2018 from a children's hospital in northern Taiwan. Participating families provided demographic and health information, with children wearing an actigraphy monitor for 7 days and mothers completing sleep and depressive mood questionnaires. We found that 76 (57.1%) of the mothers had poor sleep quality, with 65 (48.9%) mothers having a clinically significant depressive symptom score. Mean actigraphic wake after sleep onset in children was 1.42 (standard deviation = 0.51) hours, with 126 (94.7%) of the children having a clinically significant sleep disturbance score. Multivariate regression analyses showed that higher depressive symptom scores in mothers (β = 0.14; p < .01) and higher sleep disturbance scores in children (β = 0.07; p = .04) were associated with poorer maternal sleep quality, even when maternal demographic characteristics and the child's clinical and epilepsy variables were considered. Findings from our study suggest that sleep disturbances are a shared problem for mothers and their children with epilepsy. Sleep in both mothers and their children with epilepsy should be evaluated in pediatric neurologic practices, with maternal depressive symptoms screened concurrently. Future pediatric epilepsy studies are warranted to examine whether a family-based intervention program would be effective to improve sleep in mother-child dyads and to promote better health and functioning of the entire family. 相似文献
105.
106.
107.
108.
109.
Roopa Rajan MD Laura Brennan PhD Bastiaan R. Bloem MD PhD Nabila Dahodwala MD Joan Gardner RN BSN Jennifer G. Goldman MD MS David A. Grimes MD Robert Iansek PhD Norbert Kovács MD PhD Jennifer McGinley PhD Sotirios A. Parashos MD PhD Maria E.P. Piemonte PT PhD Carsten Eggers MD 《Movement disorders》2020,35(9):1509-1531
110.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献